Streetbeat News

Products Services

NTLA

Intellia Therapeutics has received FDA clearance for its IND application to initiate a pivotal Phase 3 trial of NTLA-2001 for the treatment of Transthyretin (ATTR) Amyloidosis with Cardiomyopathy.

Portfolio Pulse from Benzinga Newsdesk

October 18, 2023 | 11:01 am

SAGE

The FDA has granted Orphan Drug Designation to Sage Therapeutics' SAGE-718 for Huntington's Disease. This designation is given to drugs that are intended to treat rare diseases, providing certain benefits to the drug developer.

Portfolio Pulse from Benzinga Newsdesk

October 18, 2023 | 10:32 am

UAL

United Airlines Holdings, Inc. (NASDAQ:UAL) plans to implement a new boarding process for economy class passengers, prioritizing those with window seats. The change, referred to as WILMA (window-middle-aisle), is expected to save up to two minutes per flight and will be implemented on October 26. The company has tested the method at five airports and found it effective. The change will apply to domestic and select international flights. United's Q3 results showed a 12.5% YoY increase in total operating revenue to $14.48 billion.

Portfolio Pulse from Nabaparna Bhattacharya

October 18, 2023 | 10:13 am

AMZN

Amazon is introducing a major overhaul of its warehouse operations, known as the Sequoia System, which will reduce the time taken to fulfill orders by up to 25%, according to the Wall Street Journal.

Portfolio Pulse from Charles Gross

October 18, 2023 | 10:12 am

AZN

BGC

BIDU

GMAB

IBKR

LAC

UAL

Several US-listed stocks traded lower in Wednesday's pre-market session. BGC Group, Inc. (BGC) fell 6.2%, Genmab A/S (GMAB) declined 5.6%, United Airlines Holdings, Inc. (UAL) fell 4.9%, AstraZeneca PLC (AZN) fell 3.1%, Interactive Brokers Group, Inc. (IBKR) fell 2.9%, Lithium Americas Corp. (LAC) declined 2.7%, and Baidu, Inc. (BIDU) declined 2.7%. Factors influencing these movements include earnings reports, product approvals, and analyst ratings.

Portfolio Pulse from Lisa Levin

October 18, 2023 | 10:05 am

IMRN

Immuron Limited has commenced the second cohort of a clinical trial to evaluate the efficacy of Travelan for the prevention of infectious diarrhea caused by enterotoxigenic Escherichia coli. The study is being led by Dr Mohamed Al-Ibrahim at the Pharmaron CPC FDA inspected Clinical Research Facility Inpatient Unit in Baltimore, Maryland US.

Portfolio Pulse from Benzinga Newsdesk

October 18, 2023 | 10:03 am

GOOGL

INFY

Infosys (INFY) is expanding its alliance with Google Cloud (GOOGL) to help enterprises build AI-powered experiences. Infosys will create the new global Generative AI Labs to develop industry-specific AI solutions and platforms. Infosys will also train 20,000 practitioners on Google Cloud’s gen AI solutions, including Vertex AI and Duet AI in Google Workspace.

Portfolio Pulse from Charles Gross

October 18, 2023 | 10:03 am

BCLI

BrainStorm Cell Therapeutics is set to meet with the US FDA to discuss the development plan for NurOwn, a treatment for ALS. The company is withdrawing its Biologics License Application (BLA) for NurOwn, a decision coordinated with and viewed by the FDA as a withdrawal without prejudice. BrainStorm remains committed to the ALS community and is exploring next steps for NurOwn, including publishing emerging clinical data and developing a protocol for an additional clinical study.

Portfolio Pulse from Benzinga Newsdesk

October 18, 2023 | 10:03 am

WBA

Walgreens and the Cardiovascular Research Foundation (CRF) have announced a collaboration to advance the PREVUE-VALVE study. This clinical trial aims to quantify the prevalence of valvular heart disease (VHD) among older Americans and facilitate the development of new therapies and tools for VHD detection and diagnosis.

Portfolio Pulse from Benzinga Newsdesk

October 18, 2023 | 10:01 am

HYMTF

TSLA

Hyundai has announced a reduction in lease rates on its IONIQ 5 and IONIQ 6 electric vehicles (EVs), offering some of the lowest rates since their launch. The lease prices of these vehicles are dropping by $50 monthly, starting at approximately $229 per month. This price reduction comes after Tesla Inc. recently lowered its Model 3 lease price by up to $100 to $329 with $5,524 down. Hyundai's electric vehicles have been gaining traction in the U.S. market, with the company setting a September record with EV sales soaring 203%.

Portfolio Pulse from Benzinga Neuro

October 18, 2023 | 9:45 am